3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia
3
Prostatic Neoplasms
1
Philadelphia Chromosome
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Interventions
tofacitinib
7
Imatinib Mesylate
5
ibrutinib
3
ofatumumab
2
nilotinib
2
ruxolitinib
1
canakinumab
1
bosutinib
1
Sirolimus
1
Rituximab
1
Proto-Oncogene Proteins c-raf
1
Photopheresis
1
Pentostatin
1
Mycophenolic Acid
1
Methotrexate
1
Infliximab
1
Everolimus
1
Etanercept
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bronchiolitis Obliterans Syndrome
×
Dasatinib
×
Clear all
NCT01460693
2018-04-24
SPIRIT2
Newcastle University
Phase 3
Completed
814 enrolled